134 related articles for article (PubMed ID: 15457126)
21. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
Kannan P; Brimacombe KR; Kreisl WC; Liow JS; Zoghbi SS; Telu S; Zhang Y; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2593-8. PubMed ID: 21262843
[TBL] [Abstract][Full Text] [Related]
22. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers.
Tunggal JK; Melo T; Ballinger JR; Tannock IF
Int J Cancer; 2000 Apr; 86(1):101-7. PubMed ID: 10728602
[TBL] [Abstract][Full Text] [Related]
23. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Li C; Guan X; Xue H; Wang P; Wang M; Gai X
Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
[TBL] [Abstract][Full Text] [Related]
24. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
Hubensack M; Müller C; Höcherl P; Fellner S; Spruss T; Bernhardt G; Buschauer A
J Cancer Res Clin Oncol; 2008 May; 134(5):597-607. PubMed ID: 17932689
[TBL] [Abstract][Full Text] [Related]
25. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
Creemers SG; van Koetsveld PM; De Herder WW; Dogan F; Franssen GJH; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Mar; 26(3):367-378. PubMed ID: 30650062
[TBL] [Abstract][Full Text] [Related]
26. Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress.
Thoeringer CK; Wultsch T; Shahbazian A; Painsipp E; Holzer P
Psychoneuroendocrinology; 2007; 32(8-10):1028-40. PubMed ID: 17881135
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
28. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
Pu YS; Hsieh TS; Cheng AL; Tseng NF; Su IJ; Hsieh CY; Lai MK; Tsai TC
Br J Urol; 1996 Jan; 77(1):76-85. PubMed ID: 8653321
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors.
Gao Y; Shi W; Cui J; Liu C; Bi X; Li Z; Huang W; Wang G; Qian H
Bioorg Med Chem; 2018 May; 26(9):2420-2427. PubMed ID: 29631786
[TBL] [Abstract][Full Text] [Related]
30. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
31. Folate-Targeted Redox-Responsive Polymersomes Loaded with Chemotherapeutic Drugs and Tariquidar to Overcome Drug Resistance.
Qin Y; Zhang Z; Huang C; Fan F; Liu L; Lu L; Wang H; Liu Z; Yang J; Wang C; Yang H; Sun H; Leng X; Kong D; Zhang L; Zhu D
J Biomed Nanotechnol; 2018 Oct; 14(10):1705-1718. PubMed ID: 30041718
[TBL] [Abstract][Full Text] [Related]
32. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
33. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
Fox E; Bates SE
Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration.
Matzneller P; Kussmann M; Eberl S; Maier-Salamon A; Jäger W; Bauer M; Langer O; Zeitlinger M; Poeppl W
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):599-606. PubMed ID: 29616423
[TBL] [Abstract][Full Text] [Related]
35. Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death.
Kopecka J; Godel M; Dei S; Giampietro R; Belisario DC; Akman M; Contino M; Teodori E; Riganti C
Cells; 2020 Apr; 9(4):. PubMed ID: 32331368
[TBL] [Abstract][Full Text] [Related]
36. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
Culine S; Roch I; Pinguet F; Romieu G; Bressolle F
Int J Oncol; 1999 May; 14(5):999-1006. PubMed ID: 10200354
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins].
Yang TY; Yi W; Wen J; Gan CY; Yang YC; Dai M
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):118-123. PubMed ID: 30862141
[No Abstract] [Full Text] [Related]
38. Overcoming P-Glycoprotein-Mediated Drug Resistance with Noscapine Derivatives.
Muthiah D; Henshaw GK; DeBono AJ; Capuano B; Scammells PJ; Callaghan R
Drug Metab Dispos; 2019 Feb; 47(2):164-172. PubMed ID: 30478158
[TBL] [Abstract][Full Text] [Related]
39. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
40. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma?
Ashmore SM; Thomas DG; Darling JL
Anticancer Drugs; 1999 Nov; 10(10):861-72. PubMed ID: 10630353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
